rs1165205 — SLC17A3 SLC17A3 variant (NPT4)

SLC17A3 rs1165205 — NPT4 and the Apical Urate Exit

Every day your kidneys filter and then selectively reclaim or discard uric acid as they fine-tune the serum urate setpoint. Most people know about the reabsorptive side of this equation — transporters like URAT1¹¹ URAT1
SLC22A12, encoded by the SLC22A12 gene, is the principal apical urate reabsorber in the kidney proximal tubule; it retrieves uric acid from the tubular lumen back into the bloodstream that pull uric acid back from the urine into the blood. But secretion — actively pushing uric acid from the tubular cell into the urine — is equally important, and it depends on a distinct set of apical transporters on the urine-facing surface of the proximal tubule. One of these is NPT4²² NPT4
sodium-phosphate transporter 4, encoded by SLC17A3 on chromosome 6p22; an apical multispecific organic anion efflux transporter that drives uric acid out of tubular cells into the urine for excretion.

rs1165205 is an intronic variant in SLC17A3 that sits in the same gene cluster as SLC17A1 (encoding NPT1, the related apical urate efflux transporter). The A allele at this position is associated with higher serum uric acid in multiple populations and with reduced protection against gout. Because it is intronic, the variant likely influences NPT4 expression or mRNA processing rather than changing the protein directly — the secretory efficiency of the proximal tubule is tuned up or down depending on which version of the haplotype you carry.

The Mechanism

NPT4 operates as a voltage-driven organic anion efflux transporter³³ voltage-driven organic anion efflux transporter
the membrane potential gradient across the apical membrane provides the driving force; an increase in extracellular potassium (simulating depolarization) enhances transport activity. It transports uric acid from the interior of the proximal tubule cell into the tubular lumen, working alongside NPT1 (SLC17A1) to provide the secretory counterbalance to URAT1-mediated reabsorption. The net direction of urate movement — secretion or reabsorption — determines whether serum urate rises or falls.

When genetic variation at the rs1165205 locus impairs this secretory arm, the reabsorption-to-secretion ratio tilts toward retention, elevating the serum urate setpoint. This mechanism also explains why loop and thiazide diuretics⁴⁴ loop and thiazide diuretics
furosemide and bumetanide are competitive inhibitors of NPT4-mediated urate transport; this provides the molecular explanation for the well-known phenomenon of diuretic-induced hyperuricemia raise uric acid: they directly inhibit NPT4, reproducing the pharmacological equivalent of reduced-function genetic variants. Individuals with the A allele who also use diuretics are therefore doubly disadvantaged on urate secretory capacity.

The Evidence

rs1165205 was identified as a genome-wide significant locus for serum uric acid in the Dehghan et al. landmark GWAS published in The Lancet⁵⁵ The Lancet
Dehghan A et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet, 2008, with p=3.3×10⁻²⁶ in the Framingham cohort (7,699 participants). The protective T allele was associated with OR 0.85 (95% CI 0.77–0.94, p=0.002) for gout risk in European participants. The association was not significant in African-ancestry ARIC participants, consistent with the very high A allele frequency in African populations (~88%) leaving little statistical power to detect effects.

The GWAS Catalog reports a pooled effect of approximately 0.09 unit decrease in serum urate per T allele (p=4×10⁻²⁹) across a total sample exceeding 15,000 participants. A multi-cohort analysis (n=4,492)⁶⁶ multi-cohort analysis (n=4,492)
Brandstätter A et al. Sex and age interaction with genetic association of atherogenic uric acid concentrations. Atherosclerosis, 2010 confirmed the A allele as a component of the composite genetic risk score for elevated serum urate across European cohorts, with the SLC17A3 locus contributing modestly but consistently to the variance in serum uric acid levels.

Functional studies by Jutabha et al.⁷⁷ Jutabha et al.
Jutabha P et al. Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem, 2010 established the biological plausibility: NPT4 is the exit route for uric acid from the proximal tubule apical membrane, and loss-of-function mutations in SLC17A3 found in hyperuricemia patients abolish urate efflux capacity in cell systems. The GWAS signal at rs1165205 is consistent with a regulatory variant that modulates this secretory capacity.

Practical Actions

Elevated urate from reduced renal secretory capacity is particularly responsive to reducing dietary purine load (since the kidneys cannot compensate by increasing secretion) and to avoiding substances that further inhibit NPT4, principally loop and thiazide diuretics. Individuals with the AA genotype on diuretics should specifically flag this to their prescriber, as the pharmacological inhibition of NPT4 compounds genetically reduced secretory capacity.

Vitamin C supplementation at 500–1,000 mg/day has modest evidence for lowering serum urate by approximately 0.5 mg/dL through competitive inhibition of renal urate reabsorption — a compensatory mechanism for reduced secretory capacity. Serum uric acid monitoring establishes the individual setpoint and guides when dietary changes need reinforcement.

Interactions

rs1165205 operates at the NPT4-mediated arm of renal urate secretion. The most clinically significant interaction is with rs2231142 in ABCG2, the breast cancer resistance protein that mediates the other major apical secretory route for urate. ABCG2 Q141K (rs2231142) reduces ABCG2 activity by approximately 50%, and when combined with reduced NPT4 capacity both secretory pathways are simultaneously compromised, producing substantially higher serum urate than either variant alone. This combination is particularly relevant in East Asian populations where both risk alleles are common.

rs1165205 is also in high linkage disequilibrium (r²=0.97) with rs1183201 in the adjacent SLC17A1 gene, which encodes NPT1 — the sibling apical urate secretory transporter. The two signals tag the same haplotype block spanning the SLC17A1–SLC17A3–SLC17A4 gene cluster. Individuals carrying risk alleles at both loci may experience additive reduction in total apical secretory capacity, though these SNPs are sufficiently correlated that both rarely appear as independent effects in the same model.